The Russian pharmaceutical industry remains heavily dependent on imports of active pharmaceutical ingredients (APIs), despite efforts that have been made by the state to reduce import dependence in recent years, according to recent statements by representatives of some leading Russian pharmaceutical producers and analysts, reports The Pharma Letter’s local correspondent.
Alexander Semyonov, president of Active Component, one of Russia’s leading producers of active ingredients, said in an interview with Russian media, at present only 6%-8% of active ingredients for strategically important drugs are produced in Russia.
Mr Semyonov added that, in the case of vital medicines in Russia, the overall list of such drugs consists of 215 items, but only 162 of them are produced by chemical synthesis. Of these, only 35 drugs are obtained from chemical ingredients manufactured in Russia.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze